Back to Search
Start Over
TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.
- Source :
-
Immunotherapy [Immunotherapy] 2021 Sep; Vol. 13 (13), pp. 1135-1150. Date of Electronic Publication: 2021 Jul 08. - Publication Year :
- 2021
-
Abstract
- JAKs are intracellular protein tyrosine kinases that, through activation of STATs, are responsible for signal transduction pathways that regulate cellular responses to numerous cytokines, growth factors and hormones in many different cells. JAK-STAT signaling plays a key role in regulating immune function, and cytokines - such as IL-23, IL-12 and type I interferons - are central to the pathogenesis of autoimmune diseases, including psoriasis, inflammatory bowel disease and systemic lupus erythematosus. Here the authors review the evidence for targeting TYK2 as a more specific approach to treating these conditions. TYK2 inhibitors are clinically effective in autoimmune and inflammatory diseases and may avoid some of the complications reported with nonselective JAK inhibitors.
- Subjects :
- Autoimmune Diseases immunology
Humans
Inflammatory Bowel Diseases immunology
Lupus Erythematosus, Systemic immunology
Autoimmune Diseases drug therapy
Immunotherapy methods
Inflammatory Bowel Diseases drug therapy
Lupus Erythematosus, Systemic drug therapy
TYK2 Kinase antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1750-7448
- Volume :
- 13
- Issue :
- 13
- Database :
- MEDLINE
- Journal :
- Immunotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 34235974
- Full Text :
- https://doi.org/10.2217/imt-2021-0096